Home / Resources / Videos / ADA 2018 / Linda Parks Part 4, Is Glooko Progressing With Diabetes Care

Linda Parks Part 4, Is Glooko Progressing With Diabetes Care

In part 4 of this Exclusive Interview, Linda Parks talks with Diabetes in Control Publisher Steve Freed about how Glooko helps people to manage their diabetes.

Linda Parks, RN, is the director of Clinical Development & Research at Glooko.


Transcript of this video segment:

Freed:  How does Glooko help health care professionals in caring for people with diabetes?

Parks: I think they’re really connecting all the dots, so patients could be at home with their blood glucose monitoring, but the providers can see that data in a population stratified form with our population trackers. And so, that they can see — in the morning, if they went into their office they could quickly look at the population tracker. And we have flags there that talk about the clinical incidence whether they’re high or low and that’s something each provider sets for their own. And so, the people — their patients who may have had hyper or hypoglycemia will float to the top, so that they can quickly identify who needs to be contacted. And I think Glooko is just trying to make it a little bit easier to capture all that data in one spot, in one standard way, regardless of whatever meter or device that they’re using.

Freed: As I’ve said before technology is changing. I personally believe that we’ve come to the point in time where the blood glucose monitor is going to be the Ford Model  T—it’ll be in the museum because CGM is going to replace it. If you don’t have to stick your finger, why would you want to stick your finger 10 times a day? It is painful and there are people that don’t like the sight of blood. So, I can see that eventually there will be CGMs on the drugstore shelves and the prices will be relatively actually less than blood glucose monitors. So, what are you guys doing in that area?

Parks: Really, that’s a great point because there’s so much more dense data with the CGM which is harder to analyze. And I think products like the AGP and then Glooko will help define and analyze that data, and present it in such a way that it’s easy to look at and make decisions from because that’s what it’s all about, actionable data.

Freed: I always like to ask, what’s in the pipeline for Glooko?

Parks: So, we have lots of things in the pipeline. As we’ve talked about, it has evolved over the seven years that it’s been on the market and it will continue to evolve. One of the most exciting things now is these different advice modules that go through Glooko. So, we talked about MIDS which is for type 2 diabetes and titrating your long-acting insulin. And we also have a partnership with DreaMed which takes that CGM information and it goes through the DreaMed  engine in the background and they can recommend pump settings. And then, it’s delivered back through the health care provider through Glooko and then if the health care provider accepts the pump setting changes, then it’s delivered to the patient through their Glooko App. And DreaMed just got FDA clearance last week.

Return to the main page.